Pipeline
We are advancing the development of our best-in-class and first-in-class novel, innovative and patented* oral drug candidates for the treatment of debilitating and life threatening diseases.
Our pipeline of novel and innovative drugs are in development for the treatment of serious common and rare chronic diseases. We are focused on the development of our internally discovered innovative oral therapeutics for the treatment of chronic diseases- cardiopulmonary, renal and other serious diseases with unmet patients' medical needs.
Best-in-Class/First-in-Class Innovative Drug Candidates
• INV-610 for Obesity and weight Reduction (oral GLP-1 Drug)
• INV-240 for Pulmonary Arterial Hypertension (PAH)
• INV-122 for Chronic Kidney (Renal) disease
• INV-270 for Liver Fibrosis
• INV-331 for Alzheimer's Disease (AD) and CIAS
• INV-407 for ADHD, GAD, and MDD
• INV-290 for Neuroendocrine Tumors (SI-NET)
• INV-501 for SARS-CoV-2: Deuterated-Nirmatrelvir
*All of our above proprietary drugs in development are covered and protected by issued patents (composition-of-matter and use patents and /or patent pending)
Cardiometabolc Disease, Cardiopulmonary, and Cardiorenal and Diseases
Cardiometabolic Diseases: Obesity and Weight-Reduction
Cardiometabolic diseases continues to affect large population living with obesity, diabetes, and related comorbidities in the US and globally. INVENT is developing a novel oral Glucagon-Like Peptide (GLP-1) receptor agonist and/or GLP-1/GIP (gastric Inhibitory polypeptide) receptor modulator for the treatment of Obesity, Weight-Reduction and related metabolic diseases. Cardiometabolic diseases particularly obesity continues to be a large unmet medical need, worldwide.
Pulmonary Arterial Hypertension (PAH)
PAH is a Cardiopulmonary disease that is progressive and potentially fatal disease affecting Lung function and Heart. PAH is a severe life-threatening disease that deteriorates rapidly if left untreated. PAH is a congenital heart disease and it is fatal and progressive. PAH can also develop as a consequence of Idiopathic Pulmonary Fibrosis, COPD, Hypoxia, Portal Hypertension, or HIV infection.
Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive, irreversible and usually fatal interstitial lung disease. IPF causes shortness of breath and lung damage resulting in life-threatening respiratory failure with high mortality rate. IPF affects nearly 100,000 people in the US; IPF Patients live only 2-5 years post diagnosis.
Chronic Kidney (Renal) Disease
Chronic kidney disease (CKD) is a progressive, stealth, common and debilitating renal dysfunction condition that affects nearly 1 in 10 people worldwide. The prevalence of CKD has been increasing over the last several decades. People living with CKD progressively lose kidney function, and in many cases may not know that they have CKD until it has reached its later stages.
CKD is a highly prevalent renal disease with high unmet medical need. In addition to the increasing prevalence over the years and no drugs targeting CKD directly, CKD has become to be known as a ‘disease multiplier’ and thus not a disease to be studied in isolation. Both hypertension and diabetes are major risk factors leading to CKD. Nearly 40% of heart failure patients have CKD. Patients living with diabetes and early kidney disease may have shorter life expectancy compared to a healthy person. In addition to chronic kidney disease, there are a few rare/orphan diseases that can lead to End-Stage Renal Failure (ESRD). Renal diseases include,
• Chronic Kidney Disease (CKD)
• Acute Renal Failure (Acute impaired kidney function)
• Focal Segmental Glomerulosclerosis (FSGS)
• Immunoglobulin A Nephropathy (IgAN)
Both FSGS and IgAN are rare/orphan renal diseases that can lead to End-Stage Renal Disease (ESRD).
Neuroendocrine Tumors
Neuroendocrine Tumors (NETs) are slow-growing tumors originating from neuroendocrine cells. Neuroendocrine Neoplasms arise in the Lungs, Stomach, Small Intestine, Pancreas, Colon, Rectum, Breast, Prostate and Ovary with majority of Neuroendocrine Tumors occur in the Gastrointestinal tract (GI) and the Lungs, with 2/3rd in the Gastrointestinal tract and 1/3rd in the Lungs. Within GI-tract, most Neuroendocrine Tumors occur in the small intestine (41.8%), Rectum (27.4%), and Stomach (8.7%). Small-Intestinal Neuroendocrine Tumors (SI-NETs) are Cancers originating from enterochromaffin cells in the diffuse Neuroendocrine System. SI-NETs are slow growing and Release excessive amounts of hormones causes several different symptoms. Small-Intestine Neuroendocrine Tumors (SI-NETs) lead to Carcinoid Syndrome. SI-NETs are often present with Fibrosis in the peritumoral tissue, the adjacent mesentery and peritoneum as well as in the right side of the Heart or Lungs.
SARS-CoV-2
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) initiated the pandemic in 2020 and claimed hospitalization in multimillions and deaths globally .
Our oral antiviral drug is a novel SARS-CoV-2 Main Protease (MPro) Inhibitor with a great potential for the treatment of COVID-19 without the need of booster CYP3A inhibitor Ritonavir as in the case of Paxlovid®.
©Paxlovid® is Pfizer trademark and drug manufactured, approved and commercialized by Pfizer, Inc.
Alzheimer’s Disease
Alzheimer’s Disease (AD) is a neurodegenerative disease. AD afflicts more than 6 million people over the age of 65 in USA alone. This number will increase to nearly 12.7 million by 2050. Alzheimer’s Disease and related dementias cost the U.S. $355 Billion in 2021 and this economic burden could increase to $1.1 Trillion over the next 30 years. Alzheimer’s Disease (AD) is a Progressive Neurodegenerative disease that affects Memory, Cognition, Judgment, Language and Behavior resulting in Severe Cognitive Impairment, gradual Loss of Cognitive Function Related to Memory, Reasoning, Impaired Judgment and Orientation. Behavioral Changes in AD patients include Confusion, Depression and Aggression. The Cognitive and Behavioral Dysfunction is due to Altered Neuronal Function and Neuronal Loss in the Hippocampus and Cerebral Cortex.
Cognitive Impairment Associated with Schizophrenia (CIAS)
Schizophrenia afflicts over 21 million people globally. In the United States alone, about 2.8 million adults suffer from Schizophrenia, a serious mental illness. All Schizophrenia patients have Cognitive Impairment Associated with Schizophrenia (CIAS). CIAS is a major cause of disability in Schizophrenia patients and it poses a high unmet medical need. Schizophrenia is a chronic neuropsychiatric disorder whose symptoms include psychosis, hellucinations, delusions, paranoia, cognitive impairment, reduced motivation and social skills. Schizophrenia patients have significantly higher risk of premature mortality (death at younger age). Nearly 5% of schizophrenia patients die by suicide and the risk is highest in early stages of onset. Half of schizophrenia patients also have co-occurring mental and/or behavioral health disorders. U.S. Economic burden of schizophrenia is disproportionately higher compared to other disorders. Antipsychotic drugs are used for treating psychotic symptoms but there are no approved therapeutics for treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). Most serious adverse side effects from long-term use of old and new medicines include tardive dyskinesia, it makes facial, tongue, and neck muscles move uncontrollably and can be permanent. Other common side effects include seizures, nausea, dizziness, and blurred vision.
ADHD
Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common disorders in children and it continues into adolescence and into adulthood. One third of children retain ADHD into adulthood. Estimated 6.1 Million children and 9 Million adults were diagnosed with ADHD which is over 18% increase in ADHD patients within a decade. Current medicines used for the treatment of these mental disorders (CNS disorders) have serious and harmful adverse side effects including substance dependency, addiction, loss of appetite, loss of sleep, sexual dysfunction among adults and potential risk for suicide. Current medicines to treat mental health disorders have limited efficacy (only 1/3rd of patients are helped) and slow onset of action with multiple adverse side effects. Mental health disorders are a significant high unmet need. Safer and effective drugs are much needed for treatment of these central nervous system (CNS) disorders.
Anxiety
Over 40 Million people in the U.S. live with Anxiety disorders. Nearly 20% U.S. adults and 32% adolescents suffer from one or more types of Anxiety disorders. Five major Anxiety disorders include General Anxiety disorder, Social Anxiety disorder, Panic disorder, Post-Traumatic Stress disorder (PTSD) and Obsessive-Compulsive disorder (OCD).